07:59 AM EDT, 08/21/2024 (MT Newswires) -- Bio-Path Holdings ( BPTH ) said Wednesday that a patient treated with a higher 90 mg/m2 dose in its Phase 1/1b clinical trial of BP1001-A for solid tumors showed tumor regression and stable disease.

The company also noted "continued patient progress" in its Phase 2 triple combination study of prexigebersen in acute myeloid leukemia.

Bio-Path ( BPTH ) said supportive safety and efficacy data from both studies validate the potential of its DNAbilize platform technology to treat high-risk cancer patients.

Shares of Bio-Path ( BPTH ) were up more than 19% in Wednesday's premarket activity.

Price: 1.8190, Change: +0.33, Percent Change: +22.08